banner
You are not using a standards compliant browser. Because of this you may notice minor glitches in the rendering of this page. Please upgrade to a compliant browser for optimal viewing:
Firefox
Internet Explorer 7
Safari (Mac and PC)
Featured Article
Acne drug prevents HIV breakout

This is Janice E. Clements, Ph.D., Mary Wallace Stanton Professor of Faculty Affairs, Vice Dean for Faculty, and Professor of Molecular and Comparative Pathobiology at the Johns Hopkins University School of Medicine. Credit: Johns Hopkins Medicine
Friday, March 19, 2010

Johns Hopkins scientists have found that a safe and inexpensive antibiotic in use since the 1970s for treating acne effectively targets infected immune cells in which HIV, the virus that causes AIDS, lies dormant and prevents them from reactivating and replicating.

The drug, minocycline, likely will improve on the current treatment regimens of HIV-infected patients if used in combination with a standard drug cocktail known as HAART (Highly Active Antiretroviral Therapy), according to research published now online and appearing in print April 15 in The Journal of Infectious Diseases. "The powerful advantage to using minocycline is that the virus appears less able to develop drug resistance because minocycline targets cellular pathways not viral proteins," says Janice Clements, Ph.D., Mary Wallace Stanton Professor of Faculty Affairs, vice dean for faculty, and professor of molecular and comparative pathobiology at the Johns Hopkins University School of Medicine.

"The big challenge clinicians deal with now in this country when treating HIV patients is keeping the virus locked in a dormant state," Clements adds. "While HAART is really effective in keeping down active replication, minocycline is another arm of defense against the virus."

Unlike the drugs used in HAART which target the virus, minocycline homes in on, and adjusts T cells, major immune system agents and targets of HIV infection. According to Clements, minocycline reduces the ability of T cells to activate and proliferate, both steps crucial to HIV production and progression toward full blown AIDS.

If taken daily for life, HAART usually can protect people from becoming ill, but it's not a cure. The HIV virus is kept at a low level but isn't ever entirely purged; it stays quietly hidden in some immune cells. If a person stops HAART or misses a dose, the virus can reactivate out of those immune cells and begin to spread.

The idea for using minocycline as an adjunct to HAART resulted when the Hopkins team learned of research by others on rheumatoid arthritis patients showing the anti-inflammatory effects of minocycline on T cells. The Hopkins group connected the dots between that study with previous research of their own showing that minocycline treatment had multiple beneficial effects in monkeys infected with SIV, the primate version of HIV. In monkeys treated with minocycline, the virus load in the cerebrospinal fluid, the viral RNA in the brain and the severity of central nervous system disease were significantly decreased. The drug was also shown to affect T cell activation and proliferation.

"Since minocycline reduced T cell activation, you might think it would have impaired the immune systems in the macaques, which are very similar to humans, but we didn't see any deleterious effect," says Gregory Szeto, a graduate student in the Department of Cellular and Molecular Medicine working in the Retrovirus Laboratory at Hopkins.
"This drug strikes a good balance and is ideal for HIV because it targets very specific aspects of immune activation."

The success with the animal model prompted the team to study in test tubes whether minocycline treatment affected latency in human T cells infected with HIV. Using cells from HIV-infected humans on HAART, the team isolated the "resting" immune cells and treated half of them with minocycline. Then they counted how many virus particles were reactivated, finding completely undetectable levels in the treated cells versus detectable levels in the untreated cells.

"Minocycline reduces the capability of the virus to emerge from resting infected T cells," Szeto explains. "It prevents the virus from escaping in the one in a million cells in which it lays dormant in a person on HAART, and since it prevents virus activation it should maintain the level of viral latency or even lower it. That's the goal: Sustaining a latent non-infectious state."

The team used molecular markers to discover that minocycline very selectively interrupts certain specific signaling pathways critical for T cell activation. However, the antibiotic doesn't completely obliterate T cells or diminish their ability to respond to other infections or diseases, which is crucial for individuals with HIV.

"HIV requires T cell activation for efficient replication and reactivation of latent virus," Clement says, "so our new understanding about minocyline's effects on a T cell could help us to find even more drugs that target its signaling pathways."

###

Johns Hopkins Medical Institutions: http://www.hopkinsmedicine.org
Thanks to Johns Hopkins Medical Institutions for this article.
This article has been viewed 522 time(s).
Share This Story
Rate Article
Total votes: 0
More Health
Scientists for the first time identify a cell-of-origin for human prostate cancer

UCLA scientists have identified for the first time a cell-of-origin for human prostate cancer, a discovery that could result in better predictive and diagnostics tools and the development of new and more effective targeted treatments for the disease.

Source: University of California - Los Angeles | Views: 117 | Comments: 0
To make one happy, make one busy

In Greek mythology, the gods punished Sisyphus by condemning him to roll a rock up a steep hill for eternity. But he was probably better off than if they'd condemned him to sit and stare into space until the end of time, conclude the authors of a new study on keeping busy. They found that people who have something to do, even something pointless, are happier than people who sit idly.

Source: Association for Psychological Science | Views: 115 | Comments: 0
Small increases in vaccine cost can cause large gaps in protection

Public immunization efforts may be much more sensitive than previously realized to small changes in the perceived costs or risks of vaccination, scientists at Harvard University report this week. In some cases, the spread of vaccine avoidance via social networks can make the difference between a minor, localized outbreak and an epidemic four times as large.

Source: Harvard University | Views: 130 | Comments: 0
Western diet link to ADHD

A new study from Perth's Telethon Institute for Child Health Research shows an association between ADHD and a 'Western-style' diet in adolescents.

Source: Research Australia | Views: 487 | Comments: 0
Electronic cigarettes require more suction than conventional brands

Stronger suction is required to smoke "electronic cigarettes" – marketed as tobacco-free nicotine delivery systems – than conventional brands, with possible adverse effects on human health, researchers at the University of California, Riverside report.

Source: University of California - Riverside | Views: 147 | Comments: 0
Weight issues move up need for walkers, canes, other devices

Obese older adults are more likely to use walkers, canes and other mobility devices at a younger age, and may run the risk of using them incorrectly, according to new research from Purdue University.

Source: Purdue University | Views: 73 | Comments: 0
A man with attitude

Heterosexual women bear the brunt of narcissistic heterosexual men's hostility, while heterosexual men, gay men and lesbian women provoke a softer reaction, according to psychologist Dr. Scott Keiller from Kent State University at Tuscarawas in the US. This is likely to be due to women's unparalleled potential for gratifying, or frustrating, men's narcissism. They are crucial players and even gatekeepers in men's quests for sexual pleasure, patriarchal power and status. Dr. Keiller's findings are published online in Springer's journal Sex Roles.

Source: Springer | Views: 133 | Comments: 0
Morphine blocks tumor growth

Current research suggests that taking morphine can block new blood vessel and tumor growth. The related report by Koodie et al, "Morphine suppresses tumor angiogenesis through a HIF1α/p38MAPK pathway," appears in the August 2010 issue of the American Journal of Pathology.

Source: American Journal of Pathology | Views: 158 | Comments: 0
Advertisements
News Comments
No comments recorded.
Add Comment?
Are you a Member or a Guest?
Member Commenting:
Make your LabSpaces comments count. Start earning LabSpaces points by becoming a member!.
Learn more.
Please verify that you are human: Register for LabSpaces
Friends

CrimsonBase